Results 81 to 90 of about 862,804 (271)
Allorecognition by T lymphocytes and allograft rejection
Frontiers in Immunology, 2016 Recognition of donor antigens by recipient T cells in secondary lymphoid organs initiates the adaptive inflammatory immune response leading to the rejection of allogeneic transplants.
Gilles Benichou +2 more
doaj +1 more source
Confirmation that T cell receptor activation is digital, not analog. Hence individual T cell cytolytic capacity is independent of initial stimulation strength [PDF]
arXiv, 2018 Whether a sub-optimum lymphocyte stimulus is achieved by lowering ligand concentration, or decreasing its affinity, initial TCR activation responses are likely to be digital. We now know for cultured peripheral blood mononuclear cells (PBMCs), when activated by plant lectins such as concanavalin-A (Con-A), that the responding cells are T cells, and ...
arxiv
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential
Molecular Oncology, EarlyView.In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley +1 more source
Molecular Oncology, EarlyView.Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen +12 more
wiley +1 more source
Quantifying lymphocyte receptor diversity [PDF]
Systems Immunology, (ed. J. Das, C. Jayaprakash), Chapter 11
(2018), 2016 To recognize pathogens, B and T lymphocytes are endowed with a wide repertoire of receptors generated stochastically by V(D)J recombination. Measuring and estimating the diversity of these receptors is of great importance for understanding adaptive immunity. In this chapter we review recent modeling approaches for analyzing receptor diversity from high-
arxiv
Landscape of BRAF transcript variants in human cancer
Molecular Oncology, EarlyView.We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda +5 more
wiley +1 more source
T cell subsets' distribution in elite karate athletes as a response to physical effort [PDF]
Journal of Medical Biochemistry, 2019 Background: During karate fight muscles work at a very high intensity, and their contractions are extremely strong. The movement pattern contains a great number of feints, dodges, frequent changes in movements' tempo and direction, hits and kicks, all of
Kostrzewa-Nowak Dorota +2 more
doaj
Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer
Molecular Oncology, EarlyView.G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren +16 more
wiley +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source